5.370USD+1.32%Mkt Cap: 5.10M USDP/E: —Last update: 2026-06-01
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap5.10M USD
Enterprise Value129.78M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-34.66M USD
Revenue/Share—
Last Price5.370 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees12
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.57
PEG—
EV/EBITDA-6.79
EV/Revenue—
P/S—
P/B0.46
EPS (TTM)-3.71
EPS (Forward)-0.60
52W Range
5.0502% of range20.99
52W High20.99 USD
52W Low5.050 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-22.82%
ROA-21.34%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.52M USD
CapEx (TTM)6.66K USD
FCF Margin—
FCF Yield-265.21%
Net Debt-17.81M USD
Net Debt/EBITDA0.93
Balance Sheet
Debt/Equity0.00
Current Ratio6.29
Quick Ratio5.37
Book Value/Sh11.27 USD
Cash/Share19.43 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:28
Split DateMay 15, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.950.30K
Float835.39K
Insiders9.22%
Institutions8.62%
Short Interest
Short Ratio6.3d
Short % Float3.90%
Short % Out.3.90%
Shares Short35.76K
Short (prev mo.)49.98K
Technical
SMA 507.920 (-32.2%)
SMA 2009.522 (-43.6%)
Beta1.40
S&P 52W Chg27.70%
Avg Vol (30d)9.01K
Avg Vol (10d)14.48K
Technical Indicators
RSI (14)21.0
MACD-0.7659
MACD Signal-0.6671
MACD Hist.-0.0988
BB Upper8.360 USD
BB Middle6.611 USD
BB Lower4.861 USD
BB Width52.92%
ATR (14)0.5999 USD
Vol Ratio (20d)0.49x